REG - GlaxoSK Capital PLC - EMTN Prospectus Supplement Update

GSKAnnouncement

13/03/2020 18:35

RNS Number : 1766G
  
GlaxoSmithKline Capital PLC
  
13 March 2020
  
 

 
Issued: 13 March 2020, London UK - LSE Announcement
 
 
Publication of Supplementary Prospectus
 
The following supplementary prospectus dated 13 March 2020 has been approved by the UK Listing Authority and is available for viewing:
GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme
Copies of the supplementary prospectus and the documents incorporated by reference within it have been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:
www.morningstar.co.uk/uk/NSM
For further information, please contact:
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
 
Enquiries:



UK Media enquiries:


David Mawdsley
Simon Steel


(020) 8047 5564
(020) 8047 3763




European Analyst/Investor enquiries:


James Dodwell
Danielle Smith


(020) 8047 2406
(020) 8047 0932



 
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS
Please note that the information contained in the supplementary prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the supplementary prospectus you must ascertain from the base prospectus whether or not you are part of the intended addressees of the information contained therein. 
Your right to access this service is conditional upon complying with the above. 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
PSPSFAFWDESSEED